Company Encyclopedia
View More
name
Bayer AG
BAYN.DE
News
View More

EMA Panel Recommends EU Approval of Bayer's Aflibercept 8 mg for Retinal Vein Occlusion

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended Bayer AG's aflibercept 8 mg for marketing authorization in the EU for treating visual impairment due to macular edema following retinal vein occlusion. This would be the third indication for Eylea 8 mg in the EU. The European Commission's final decision is expected soon.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Bayer AG’s AskBio Wins Japan SAKIGAKE Designation for Gene Therapies

Bayer AG's subsidiary, AskBio, has received the SAKIGAKE designation from Japan's Ministry of Health for two gene therapy programs, AB-1005 for Parkinson's disease and AB-1002 for heart failure. This designation aims to expedite regulatory review in Japan, marking Bayer's first recognition of this kind in the country. Both therapies are investigational and not yet approved by any regulatory authority.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 5.41%

Goldman Sachs Group, Inc. has increased its voting rights in Bayer AG from 5.14% to 5.41%, marking a 0.27 percentage point rise. This change was reported by Bayer AG through EQS News on December 5, 2025. The information is provided by Public Technologies using AI and is not financial advice.

Reuters·
US
GS
-2.53%
DE
BAYN
0.00%
Reuters·
US
GS
-2.53%
DE
BAYN
0.00%

Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 3.17%

Goldman Sachs Group has increased its total voting rights in Bayer AG from 4.75% to 5.14%, a rise of 0.39 percentage points.

Reuters·
US
GS
-2.53%
DE
BAYN
0.00%
Reuters·
US
GS
-2.53%
DE
BAYN
0.00%

Bayer Launches Phase IIa Trial of BAY 3401016 for Alport Syndrome

Bayer AG has initiated a Phase IIa clinical trial for BAY 3401016, targeting Semaphorin 3A in Alport Syndrome. The ASSESS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BAY 3401016 in adult patients. The drug has received Fast Track and Orphan Drug Designation from the U.S. FDA. The study has just commenced, and results are not yet available.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%
© 2025 Longbridge｜Disclaimer